obesity-and-nash-summit.com Open in urlscan Pro
5.134.13.35  Public Scan

Form analysis
1 forms found in the DOM

GET https://obesity-and-nash-summit.com/

<form role="search" method="get" id="searchform" class="searchform" action="https://obesity-and-nash-summit.com/">
  <div>
    <label class="screen-reader-text" for="s"> Search</label>
    <input type="text" value="" name="s" id="s" placeholder="">
    <input type="submit" id="searchsubmit" value="Search">
  </div>
</form>

Text Content

Skip to content


NOVEMBER 29 - DECEMBER 1, 2022
BOSTON, MA


Access Brand-New Agenda
Menu

 * Home
 * About
   * About Event
   * Venue
   * Testimonials
   * Media Hub
 * Program
   * Full Event Guide
   * 2022 Speakers
   * Pre-Conference Seminar Day
   * Agenda
     * Conference Day 1
     * Conference Day 2
 * Partner
   * Partner With Us
   * 2022 Partners
 * Get Involved
   * Register
   * Contact Us


EVENT PROGRAM
REGISTER
PARTNER WITH US


WELCOME TO THE 6TH OBESITY & NASH DRUG DEVELOPMENT SUMMIT

There has been a rise and fall of investment in NASH in the wake of highly
demanding biopsy endpoints and late-stage clinical setbacks. However, a surge of
interest in approaching metabolic syndrome more holistically, pivotal readouts
in GLP-1 receptor agonists for the treatment of obesity, and trailblazing
approaches to innovative trial design have resurrected and transformed the
landscape for drug development in obesity, NASH, and other metabolic disorders.

Uniting industry experts dedicated to accelerating the frontier of therapeutic
development in metabolic syndrome, the 6th Obesity & NASH Drug Development
Summit (previously the NASH Summit), is the definitive industry forum sharing
cross-industry insight to drive holistic approaches to drug development in
metabolic syndrome.

Join 150+ industry experts from Novo Nordisk, Eli Lilly, Boehringer Ingelheim,
Pfizer, Inventiva, Regeneron, Bayer, Gilead, FDA, AstraZeneca, and many more
confirmed to attend. With sessions from delineating the latest advances in
exciting targets including GLP-1 receptor agonists and progress in regenerative
medicine, to reimagining inclusion criteria in clinical trials, this is your
opportunity to de-risk the pathway to life-changing therapeutics for obesity,
NASH and type 2 diabetes.

As we are at the precipice of unprecedented validation of non-invasive
biomarkers, breakthroughs in exciting targets, and a reimagined approach to
patient inclusion in trials with precision medicine, this is a conversation you
won’t want to miss.




OUR 2022 SPEAKER FACULTY:

JACOB JEPPESEN

Vice President Type 2 Diabetes & Cardiovascular Disease Research

Novo Nordisk



MATHIJS BUNCK

Associate Vice President, Medical Development, Tirzepatide Obesity

Eli Lilly & Company



RANABIR SINHAROY

Vice President & Global Program Head General Medicine

Regeneron




GINNIE (HSIU-CHIUNG) YANG

Vice President, Therapeutic Area 2, Inflammation, Exploratory Pathobiology,
Tissue Repair

Bayer



MICHELLE LONG

International Medical Vice President, NASH

Novo Nordisk



SARAH SHERLOCK

Senior Director, Clinical & Translational Imaging & Head of External Imaging
Alliances

Pfizer



SEE FULL SPEAKER FACULTY



WHY IS THE INDUSTRY EXCITED TO ATTEND:





PROUD TO PARTNER WITH













OTHER EVENTS IN THE SERIES




OUR CONTACT DETAILS

T:  (+1) 617 455 4188
E: info@hansonwade.com


VENUE DETAILS

Revere Boston Common
200 Stuart St
Boston
MA 02116
United States


ABOUT US

Hanson Wade's goal is to accelerate progress within organisations and across
industries. Our primary method for achieving this is by creating exclusive
business conferences that gather together the world's smartest thinkers and
doers.


EVENT DETAILS




SEARCH

Search


ORGANISED BY



Terms & Conditions



© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade
Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.

We use cookies to ensure that we give you the best experience on our website. If
you continue to use this site we will assume that you are happy with it.Ok

×
We Value Your Privacy
Settings
NextRoll, Inc. ("NextRoll") and our advertising partners use cookies and similar
technologies on this site and use personal data (e.g., your IP address). If you
consent, the cookies, device identifiers, or other information can be stored or
accessed on your device for the purposes described below. You can click "Allow
All" or "Decline All" or click Settings above to customize your consent.
NextRoll and our advertising partners process personal data to: ● Store and/or
access information on a device; ● Create a personalized content profile; ●
Select personalised content; ● Personalized ads, ad measurement and audience
insights; ● Product development. For some of the purposes above, our advertising
partners: ● Use precise geolocation data. Some of our partners rely on their
legitimate business interests to process personal data. View our advertising
partners if you wish to provide or deny consent for specific partners, review
the purposes each partner believes they have a legitimate interest for, and
object to such processing.
If you select Decline All, you will still be able to view content on this site
and you will still receive advertising, but the advertising will not be tailored
for you. You may change your setting whenever you see the Manage consent
preferences on this site.
Decline All
Allow All
Manage consent preferences